Journal article

PREDICT Plus: development and validation of a prognostic model for early breast cancer that includes HER2

GC Wishart, CD Bajdik, E Dicks, E Provenzano, MK Schmidt, M Sherman, DC Greenberg, AR Green, KA Gelmon, V-M Kosma, JE Olson, MW Beckmann, R Winqvist, SS Cross, G Severi, D Huntsman, K Pylkas, I Ellis, TO Nielsen, G Giles Show all

British Journal of Cancer | NATURE PUBLISHING GROUP | Published : 2012


Awarded by Breast Cancer Campaign, Cancer Research UK

Awarded by US National Institutes of Health

Awarded by Academy of Finland

Awarded by Dutch Cancer Society

Awarded by National Institute for Health Research

Awarded by The Francis Crick Institute



Funding Acknowledgements

We thank all the patients who took part in the component BCAC studies and the many other individuals who have made these studies possible. In particular, we thank Hans Peterse, Rob Tollenaar, Vincent Smit, Renate de Groot, Renate Udo, Flora van Leeuwen (ABCS); Claudia Rauh, Julia Wessel (BBCC); the BC Cancer Registry and Breast Cancer Outcomes Unit (BCCA); Paivi Heikkila, Kirsimari Aaltonen, Kristiina Aittomaki,Ari Ristimaki, Laura Hautala, Mira Heinonen, RN Hanna Jantti, Irja Erkkila, and the Finnish Cancer Registry (HEBCS); Lars A Akslen (JGH); Vicky Cafourek, Matthew Kosel and Zachary Fredericksen (MCBCS); John Hopper, Dallas English and Helen Kelsall (MCCS), (NOBCS); Arja Jukkola-Vuorinen, Taina Turpeenniemi-Hujanen, Mervi Grip, Saila Kauppila, Kari Mononen and Meeri Otsukka (OBCS); Louise Brinton, Jonine Figueroa, Kelly Bolton, Neonila, Szeszenia-Dabrowska, Beata Peplonska, Witold Zatonski, Pei Chao, and Michael Stagner (PBCS); Sabapathy, Balasubramanian, Malcolm WR Reed, Helen Cramp, and Dan Connley (SBCS); Sarah-Jane Dawson and the SEARCH team (SEARCH). The contributing studies are funded by grants from Breast Cancer Campaign (2004Nov49), Cancer Research UK (C490/A10119, C490/A10124); US National Institutes of Health (CA122340, CA122340Z, CA116201); special Government Funding (EVO) of Kuopio University Hospital; the Cancer Fund of North Savo; the Finnish Cancer Organisation; the Academy of Finland (132473); strategic funding of the University of Eastern Finland; the Helsinki University Central Hospital Research Fund; the Finnish Cancer Society; the Sigrid Juselius Foundation; Susan G Komen for the Cure, Yorkshire Cancer Research. GCW and CC received research funding from the Cambridge NIHR Biomedical Research Centre and the Cambridge Experimental Cancer Medicine Centre. CDB, TN and DH are partly supported through Career Awards from the Michael Smith Foundation For Health Research. MKS is funded by the Dutch Cancer Society (NKI DCS 2009-4363).